Roche launches new chromogen for cancer research

Tucson, Arizona

March 11, 2016

DISCOVERY Yellow Kit to advance IHC and ISH multiplexing  

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the DISCOVERY Yellow Kit1, the newest addition to the comprehensive collection of VENTANA modular-based detection kits to aid in the identification and profiling of cancer biomarkers and tumour cell populations. DISCOVERY Yellow is an alkaline phosphatase-based detection chemistry for tissue diagnostics that produces a unique, transparent yellow signal that is not washed away during alcohol dehydration like some precipitating dyes, fitting seamlessly into routine laboratory workflow.

This unique detection kit fosters innovative research with the DISCOVERY ULTRA2, a fully automated immunohistochemistry (IHC) and in situ hybridization (ISH) staining platform. It can be used in combination with other dyes, expanding IHC and ISH multiplexing capability, by providing a distinct color that contrasts with other chromogens. The DISCOVERY Yellow color is complementary to other modular chromogens including DISCOVERY Purple, DISCOVERY Red and DISCOVERY Silver, giving users a variety of chromogens to choose from for multiplexing in which multiple markers can be simultaneously studied with limited tissue samples.

Highly significant to innovative research, DISCOVERY Yellow is designed to be used in conjunction with other chromogens for detecting signal co-localization, in which the spatial overlapping of two signals can be studied by forming a third color.


By providing additional staining detection flexibility to the research community, we give our customers more options in their multiplexing applications, allowing for further advancement in their biomarker research, said Ann Costello, Head, Roche Tissue Diagnostics. Our beta test customers are very impressed with the strong, distinct, crisp and transparent staining quality by DISCOVERY Yellow on different types of tissue.


DISCOVERY Yellow Kit is supplied in ready-to-use dispensers that can be fully automated on the DISCOVERY ULTRA system to empower researchers with increased flexibility and unprecedented productivity for increasingly complex assay requirements.


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit


All trademarks used or mentioned in this release are legally protected by law.



  1. Research Use Only. Not for use in diagnostic procedure.
  2. Research platform.

For Further Information

Gabrielle Fimbres

Sr. Manager of External Communications
[email protected]